| |
| |
|
| Insider
Information: |
Walker John Peter |
| Relationship: |
President & CEO, Direc... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
394,450 |
|
|
Indirect Shares
|
60,840 |
|
|
| Direct
Value |
$337,297 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
455,290 |
|
|
| Total
Value |
$337,297 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Renovis Inc |
RNVS |
Director |
2008-05-02 |
0 |
2006-12-15 |
60,840 |
Premium* |
|
|
Geron Corporation |
GERN |
Director |
2009-01-30 |
39,119 |
2005-05-06 |
0 |
Premium* |
|
|
Paratek Pharmaceuticals Inc |
PRTK |
Chief Executive Office... |
2008-09-19 |
75,103 |
2008-01-14 |
0 |
Premium* |
|
|
Affymax Inc |
AFFY |
Director |
2013-08-28 |
0 |
2011-12-19 |
0 |
Premium* |
|
|
Zosano Pharma Corp |
ZSAN |
President & CEO, Direc... |
2019-04-11 |
280,228 |
2016-08-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
43 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GERN |
Geron Corporation |
Director |
– • – |
2009-01-30 |
4 |
OE |
$3.97 |
$229,084 |
D/D |
48,617 |
87,736 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2006-02-27 |
4 |
S |
$21.65 |
$433,785 |
I/I |
(20,000) |
100,840 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2005-05-12 |
4 |
S |
$18.00 |
$180,000 |
I/I |
(10,000) |
120,840 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-08-12 |
4 |
A |
$0.00 |
$0 |
D/D |
129,537 |
130,840 |
|
- |
|
| ZSAN |
Zosano Pharma Corp |
Interim CEO |
• • – |
2017-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
133,178 |
0 |
- |
|
| RNVS |
Renovis Inc |
Executive Chairman |
• • – |
2007-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
160,840 |
0 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-11-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(952,346) |
166,005 |
|
- |
|
| ZSAN |
Zosano Pharma Corp |
Interim CEO |
• • – |
2017-05-24 |
4 |
B |
$1.34 |
$48,553 |
D/D |
36,166 |
169,344 |
2.81 |
- |
|
| ZSAN |
Zosano Pharma Corp |
President and CEO |
• • – |
2017-08-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(26,666) |
180,228 |
0 |
- |
|
| ZSAN |
Zosano Pharma Corp |
Interim CEO |
• • – |
2017-05-25 |
4 |
B |
$1.37 |
$51,338 |
D/D |
37,550 |
206,894 |
2.81 |
- |
|
| ZSAN |
Zosano Pharma Corp |
President & CEO |
• • – |
2019-04-11 |
4 |
B |
$3.50 |
$350,000 |
D/D |
100,000 |
280,228 |
2.81 |
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-09-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,519) |
1,118,351 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-09-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(454) |
1,123,870 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-08-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(378,209) |
1,124,324 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-08-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,976) |
1,502,533 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-08-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(282,723) |
1,504,509 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-08-02 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,034,989) |
1,787,232 |
|
- |
|
| RNVS |
Renovis Inc |
Director |
– • – |
2004-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
2,822,221 |
2,577,777 |
|
- |
|
43 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
